X
feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
Medientyp
Sprache
Region
Bibliothek
Erscheinungszeitraum
Person/Organisation
Fachgebiete(RVK)
Schlagwörter
Zugriff
  • 1
    Buch
    Buch
    Patent strategy in pharmaceutical industry : are additional patents valuable? (2014)
    Baden-Baden : Nomos
    Details
    UID:
    b3kat_BV041756017
    Umfang: 84 S. , graph. Darst.
    Ausgabe: 1. Aufl.
    ISBN: 9783848709915 , 3848709910
    Serie: MIPLC studies 20
    Anmerkung: Zugl.: Munich, Munich Intellectual Property Law Center, Masterarbeit, 2012
    Weitere Ausg.: Erscheint auch als Online-Ausgabe ISBN 978-3-8452-5128-8
    Sprache: Englisch
    Fachgebiete: Rechtswissenschaft
    RVK:
    PJ 2960
    RVK:
    PJ 2880
    Schlagwort(e): Pharmazeutische Industrie ; Patentschutz ; Hochschulschrift
    URL: Volltext  (kostenfrei)
    URL: Inhaltsverzeichnis
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Buch
    Volltext
    EUV Frankfurt get availability status
    BTU Cottbus get availability status
  • 2
    Online-Ressource
    Online-Ressource
    Patent strategy in pharmaceutical industry : are additional patents valuable? (2014)
    Nomos Verlagsgesellschaft mbH & Co. KG | Baden-Baden, [Germany] :Nomos,
    Details
    UID:
    almahu_9949711193702882
    Umfang: 1 online resource (85 p.)
    Ausgabe: 1. Auflage.
    ISBN: 3-8452-5128-X
    Serie: Munich Intellectual Property Law Center Studies ; Volume 20
    Inhalt: This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.
    Anmerkung: Description based upon print version of record. , Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry - The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices , f) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German , Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others , English
    Weitere Ausg.: ISBN 3-8487-0991-0
    Sprache: Englisch
    Schlagwort(e): Electronic books ; Hochschulschrift
    URL: Volltext  (kostenfrei)
    URL: kostenfrei
    URL: Volltext  (kostenfrei)
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Online-Ressource
    Volltext
    Volltext
    Stabi Berlin
    HU Berlin
  • 3
    Online-Ressource
    Online-Ressource
    Patent strategy in pharmaceutical industry : are additional patents valuable? (2014)
    Baden-Baden : Nomos Verlagsgesellschaft
    Details
    UID:
    gbv_1066614555
    Umfang: 1 Online-Ressource (85 pages)
    Ausgabe: 1. Aufl
    ISBN: 9783845251288 , 384525128X , 384525128X , 9783845251288
    Serie: MIPLC studies v. 20
    Inhalt: Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry -- The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices
    Inhalt: F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German
    Inhalt: F) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German
    Inhalt: Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als "evergreening" bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter "Blockbuster"--Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung. Reihe Munich Intellectual Property Law Center - MIPLC - Band 20
    Anmerkung: Includes bibliographical references
    Weitere Ausg.: ISBN 9783848709915
    Weitere Ausg.: ISBN 9783848709915
    Weitere Ausg.: Erscheint auch als Druck-Ausgabe Donghi, Monica Patent strategy in pharmaceutical industry: are additional patents valuable? Baden-Baden : Nomos, 2014 ISBN 3848709910
    Weitere Ausg.: ISBN 9783848709915
    Weitere Ausg.: Print version Donghi, Monica Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? Baden-Baden : Nomos Verlagsgesellschaft, ©2014 ISBN 9783848709915
    Sprache: Englisch
    Fachgebiete: Rechtswissenschaft
    RVK:
    PJ 2960
    Schlagwort(e): Electronic books
    URL: Volltext  (kostenfrei)
    URL: kostenfrei
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Online-Ressource
    Volltext
    Stabi Berlin
  • 4
    Online-Ressource
    Online-Ressource
    Patent strategy in pharmaceutical industry : are additional patents valuable? (2014)
    Nomos Verlagsgesellschaft mbH & Co. KG | Baden-Baden, [Germany] :Nomos,
    Details
    UID:
    edoccha_9958982584902883
    Umfang: 1 online resource (85 p.)
    Ausgabe: 1. Auflage.
    ISBN: 3-8452-5128-X
    Serie: Munich Intellectual Property Law Center Studies ; Volume 20
    Inhalt: This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.
    Anmerkung: Description based upon print version of record. , Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry - The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices , f) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German , Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others , English
    Weitere Ausg.: ISBN 3-8487-0991-0
    Sprache: Englisch
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Online-Ressource
    Charité
  • 5
    Online-Ressource
    Online-Ressource
    Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? (2014)
    Baden-Baden : Nomos Verlagsgesellschaft mbH & Co. KG
    Details
    UID:
    almahu_9947932683802882
    Umfang: 1 online resource
    Ausgabe: 1. Auflage 2014
    ISBN: 9783845251288 (Online) , 9783848709915 (Print)
    Inhalt: Dieses Buch untersucht die Lifecycle-Management-Strategien, die von Pharma-Unternehmen eingesetzt werden, um den Wert ihres Produktportfolios zu maximieren. Solche Strategien werden manchmal von Generika-Unternehmen als „evergreening“ bezeichnet. Die Analyse erfolgt anhand zwei zufällig ausgewählter „Blockbuster“-Medikamente, Taxotere und Xalatan und konzentriert sich auf zwei dieser Strategien, nämlich die Produktverbesserung und die Produktlinienerweiterung.
    Sprache: Englisch
    URL: https://doi.org/10.5771/9783845251288
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Online-Ressource
    HU Berlin
  • 6
    Online-Ressource
    Online-Ressource
    Patent strategy in pharmaceutical industry : are additional patents valuable? (2014)
    Nomos Verlagsgesellschaft mbH & Co. KG | Baden-Baden, [Germany] :Nomos,
    Details
    UID:
    edocfu_9958982584902883
    Umfang: 1 online resource (85 p.)
    Ausgabe: 1. Auflage.
    ISBN: 3-8452-5128-X
    Serie: Munich Intellectual Property Law Center Studies ; Volume 20
    Inhalt: This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown.
    Anmerkung: Description based upon print version of record. , Acronyms and Abbreviations; I. Introduction; II. Background; A. Pharmaceutical Industry - The Development of a New Drug.; B. New Drug Approval Regulations; C. Generic Drugs Approval.; III. Case Studies-Facts; A. Taxotere; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Derivatives; 3. Use of Procedural Provisions: Supplementary Protection Certificates (SPCs)/Patent Term Extension; 4. Conclusion; B. Xalatan; 1. General; 2. Patent Portfolio; a) Process; b) Formulation; c) Combination Therapy; d) New Uses; e) Delivery Devices , f) Packaged Product3. Use of Procedural Provisions; a) Divisional of Basic Patent; b) Supplementary Protection; 4. Conclusion; IV. Discussion; A. Lifecycle Management: Criticism and Supports; B. Further Filing Strategy: Commercial Value; 1. Innovation Tracks; a) Formulations; b) Combinations; c) Process; d) New Uses; e) Delivery Devices; 2. Xalatan SPC Request: a Case for Competition Law?; C. Patent Strategy and Innovation; D. Summary: Taxotere v Xalatan; E. Conclusion and Suggestions; V. Final Remarks; List of works cited; Periodical Materials in English; Periodical Material in German , Non Periodical MaterialTable of books; Table of Cases; European Union; EPO Board of Appeal; France; Germany; Italy; United Kingdom; United States; Statutes; Speeches and Reports; Press release; Others , English
    Weitere Ausg.: ISBN 3-8487-0991-0
    Sprache: Englisch
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
    Online-Ressource
    FU Berlin
Nichts oder nicht das Richtige gefunden? Bitte überprüfen Sie Ihre Suchanfrage oder benutzen Sie den Fernleihindex.
Meinten Sie 3848701510?
Meinten Sie 3848700190?
Meinten Sie 3848700980?
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie auf den KOBV Seiten zum Datenschutz